Semaglutide Shows Greater Glycemic Control and Reduction in Body Weight Than Dulaglutide

Date: 
January, 2018

January 31, 2018. This randomized, open label, parallel-group, phase 3b clinical trial evaluated the impact of dulaglutide vs semaglutide (both dipeptidyl peptidase-4 inhibitors) on A1C and body weight. For 40 weeks, participants with type 2 diabetes received either dulaglutide 0.75 mg (n=299), dulaglutide 1.5 mg (n=299), semaglutide 0.5 mg (n=301), or semaglutide 1.0 mg (n=300) in addition to metformin. Patients receiving either semaglutide dose had greater numerical mean reductions in A1C from baseline compared with either dulaglutide dose, with an estimated treatment difference of -0.40% (95% confidence interval [CI]: -0.55 to -0.25; P<0.0001) and -0.41% (95% CI: -0.57 to -0.25; P<0.0001) in the low- and high-dose groups, respectively. The same pattern held true for body weight, with an estimated treatment difference of -2.26 kg (95% CI: -3.02 to -1.51; P<0.0001) and -3.55 kg (95% CI: -4.32 to -2.78; P<0.0001) for the low- and high-dose groups, respectively. The safety profile of both drugs was similar, with gastrointestinal disorders noted as the most frequent adverse event. You can read the study abstract here.